Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis

por Landau, H, Smith, M, Landry, C, Chou, J F, Devlin, S M, Hassoun, H, Bello, C, Giralt, S, Comenzo, R L
Publicado 2017

A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas

por Lee, J K, Capanu, M, O'Reilly, E M, Ma, J, Chou, J F, Shia, J, Katz, S S, Gansukh, B, Reidy-Lagunes, D, Segal, N H, Yu, K H, Chung, K-Y, Saltz, L B, Abou-Alfa, G K
Publicado 2013